Last reviewed · How we verify
Group VTI
VTI-0521 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.
VTI-0521 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Group VTI |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Drug class | sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting Nav1.5, VTI-0521 is thought to reduce the risk of atrial fibrillation and subsequent stroke. This is achieved through a mechanism that involves the modulation of cardiac ion channels, leading to a reduction in atrial fibrillation burden.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- The Effect of CUGP Fluid Management in Patients With Sepsis or Septic Shock (NA)
- Transhepatic Echography for Fluid Responsiveness After Cardiovascular Surgery
- Assessment of Agreement Between Two Measurement Methods of Left Ventricular Outflow Tract (LVOT) Velocity Time Integral (VTI) (NA)
- Hemodynamic Monitoring and Fluid Responsiveness in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) - "HemodynamECMOnitoring-VA Study" (NA)
- Hemodynamic Monitoring and Fluid Responsiveness in Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) - "HemodynamECMOnitoring-VV Study" (NA)
- Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock (NA)
- Evaluation of Left Ventricular Function to Predict Weaning Success in the Intensive Care Unit
- Prognostic Value of the LVOT VTI in STEMI Patients Undergoing PPCI
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |